GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » PS Ratio

CLPT (ClearPoint Neuro) PS Ratio : 13.25 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ClearPoint Neuro's share price is $15.325. ClearPoint Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.16. Hence, ClearPoint Neuro's PS Ratio for today is 13.25.

Warning Sign:

ClearPoint Neuro Inc stock PS Ratio (=14.17) is close to 2-year high of 14.17

The historical rank and industry rank for ClearPoint Neuro's PS Ratio or its related term are showing as below:

CLPT' s PS Ratio Range Over the Past 10 Years
Min: 0.84   Med: 6.16   Max: 35.88
Current: 13.97

During the past 13 years, ClearPoint Neuro's highest PS Ratio was 35.88. The lowest was 0.84. And the median was 6.16.

CLPT's PS Ratio is ranked worse than
88.7% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 3.29 vs CLPT: 13.97

ClearPoint Neuro's Revenue per Sharefor the three months ended in Sep. 2024 was $0.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.16.

During the past 12 months, the average Revenue per Share Growth Rate of ClearPoint Neuro was 27.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 5.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was -12.60% per year.

During the past 13 years, ClearPoint Neuro's highest 3-Year average Revenue per Share Growth Rate was 6.40% per year. The lowest was -36.50% per year. And the median was -21.40% per year.

Back to Basics: PS Ratio


ClearPoint Neuro PS Ratio Historical Data

The historical data trend for ClearPoint Neuro's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro PS Ratio Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.63 19.64 14.27 9.96 6.97

ClearPoint Neuro Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.52 6.97 6.46 4.91 9.69

Competitive Comparison of ClearPoint Neuro's PS Ratio

For the Medical Devices subindustry, ClearPoint Neuro's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's PS Ratio distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's PS Ratio falls into.



ClearPoint Neuro PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

ClearPoint Neuro's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.325/1.157
=13.25

ClearPoint Neuro's Share Price of today is $15.325.
ClearPoint Neuro's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.16.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


ClearPoint Neuro  (NAS:CLPT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


ClearPoint Neuro PS Ratio Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103